Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Equity Average (2018 - 2025)

Arcturus Therapeutics Holdings' Equity Average history spans 8 years, with the latest figure at $219.3 million for Q4 2025.

  • For Q4 2025, Equity Average fell 12.79% year-over-year to $219.3 million; the TTM value through Dec 2025 reached $219.3 million, down 12.79%, while the annual FY2025 figure was $227.5 million, 12.42% down from the prior year.
  • Equity Average reached $219.3 million in Q4 2025 per ARCT's latest filing, down from $227.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $374.6 million in Q1 2021 to a low of $158.2 million in Q3 2022.
  • Average Equity Average over 5 years is $255.5 million, with a median of $255.8 million recorded in 2024.
  • Peak YoY movement for Equity Average: soared 1651.44% in 2021, then plummeted 46.0% in 2022.
  • A 5-year view of Equity Average shows it stood at $243.7 million in 2021, then dropped by 14.64% to $208.0 million in 2022, then soared by 34.28% to $279.3 million in 2023, then fell by 9.98% to $251.4 million in 2024, then fell by 12.79% to $219.3 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Equity Average are $219.3 million (Q4 2025), $227.8 million (Q3 2025), and $232.4 million (Q2 2025).